Amgen Denied Full Fed. Circ. Hearing On Repatha Patents
The full Federal Circuit will not review a panel decision that revived a challenge to Amgen's patents for Repatha, an antibody-based cholesterol treatment, according to a decision issued by the appeals...To view the full article, register now.
Already a subscriber? Click here to view full article